Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single‐arm, phase 2 trial.

MLA

Palmerini, Emanuela, et al. “Nivolumab and Sunitinib in Patients with Advanced Bone Sarcomas: A Multicenter, Single‐arm, Phase 2 Trial.” Cancer (0008543X), vol. 131, no. 1, Jan. 2025, pp. 1–14. EBSCOhost, https://doi.org/10.1002/cncr.35628.

APA

Palmerini, E., Lopez Pousa, A., Grignani, G., Redondo, A., Hindi, N., Provenzano, S., Sebio, A., Lopez Martin, J. A., Valverde, C., Martinez Trufero, J., Gutierrez, A., de Alava, E., Aparisi Gomez, M. P., D’Ambrosio, L., Collini, P., Bazzocchi, A., Moura, D. S., Ibrahim, T., Stacchiotti, S., & Broto, J. M. (2025). Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single‐arm, phase 2 trial. Cancer (0008543X), 131(1), 1–14. https://doi.org/10.1002/cncr.35628

Chicago

Palmerini, Emanuela, Antonio Lopez Pousa, Giovanni Grignani, Andres Redondo, Nadia Hindi, Salvatore Provenzano, Ana Sebio, et al. 2025. “Nivolumab and Sunitinib in Patients with Advanced Bone Sarcomas: A Multicenter, Single‐arm, Phase 2 Trial.” Cancer (0008543X) 131 (1): 1–14. doi:10.1002/cncr.35628.